timothy sykes logo
TEM Stock Jumps As Tempus AI Lands Big Pharma Data Deals Thumbnail
G Google News

TEM Stock Jumps As Tempus AI Lands Big Pharma Data Deals

JACK KELLOGG•UPDATED NOV. 2, 2026, 11:32 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Tempus AI Inc. stocks have been trading up by 10.52 percent amid heightened optimism over its AI-driven healthcare advances.

Key Takeaways

  • Multi‑year Bristol Myers Squibb deal makes the pharma giant one of Tempus AI’s largest licensors of de‑identified oncology data through 2031, anchored on the Lens AI platform.
  • New five‑year, $55M Pathos agreement pushes Tempus AI into neurology with a large longitudinal dataset and a three‑party collaboration with Bristol Myers Squibb.
  • Expanded Moderna and Merck collaboration locks TEM deeper into individualized cancer therapy workflows via next‑generation sequencing and sample logistics.
  • Despite bullish partnerships, TEM dipped about 2.9% in pre‑market trading after the Moderna–Merck news, flagging execution and profitability worries.

Candlestick Chart

Live Update At 11:32:04 EST: On Monday, November 02, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 10.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM has been trading like a textbook momentum name. Over the last several sessions, Tempus AI Inc. climbed from the mid‑$60s to close near $79.95, a sharp bounce from the 2026/10/26 low around $64.03. That is a powerful grind higher, with higher lows stacking from 2026/10/20 onward, telling traders that dip buyers remain in control.

Intraday, TEM shows strong liquidity and wide intraday ranges. On the latest session, shares flushed at the open toward $70.30, then ripped to $80.70 before settling just under $80. For active traders, that $10 intraday range is gold — it offers clear levels to trade against and enough volatility for both breakouts and failed‑follow‑through setups.

More Breaking News

Under the hood, Tempus AI is still a growth story, not a profitability machine. Revenue sits near $1.27B, with a strong 73.5% gross margin but negative operating margins and free cash flow. TEM is priced like a high‑expectation platform play at roughly 9x sales and a rich price‑to‑book ratio. The balance sheet, however, shows solid liquidity with a current ratio around 3.3, giving Tempus AI some runway to keep funding growth while traders focus on execution against its expanding contract base.

Why Traders Are Watching Tempus AI Now

TEM is back in focus because Tempus AI just stacked several heavyweight pharma deals in rapid succession. The headline move is the multi‑year agreement with Bristol Myers Squibb that runs through 2031. BMS will license Tempus AI’s multimodal oncology data and tap its GPU‑enabled Lens AI platform to speed up drug discovery and clinical development. For traders, the key words are “through 2031” and “one of the largest licensors.” That screams visibility and scale.

This is not a one‑off contract. It deepens an existing relationship and positions Tempus AI Inc. as core infrastructure in BMS’s oncology engine. When a top‑tier pharma commits to that kind of long‑dated data licensing, it sends a strong signal that TEM’s datasets and AI stack have real staying power.

At the same time, Tempus AI is using its oncology backbone to break into neurology. The five‑year, $55M Pathos deal pays TEM to curate a de‑identified longitudinal dataset in neurological conditions, including hundreds of thousands of patients. Pathos will run the data through its Foundry AI platform for Alzheimer’s and other neurological drug development, with Bristol Myers Squibb again in the mix as part of a three‑party collaboration. Traders should read that as proof that the Tempus AI model is portable across disease areas.

On top of that, TEM expanded its multi‑year collaboration with Moderna and Merck around intismeran autogene, an individualized neoantigen therapy paired with KEYTRUDA. Tempus AI will manage tumor and blood sample logistics and provide next‑generation sequencing for design and manufacturing. The stock traded about 2.9% lower pre‑market after that headline, likely on near‑term cost and execution concerns, but the strategic setup ties TEM directly to a potential new wave of precision oncology products.

Conclusion

Put all this together and TEM is shaping up as a pure‑play bet on AI‑driven precision medicine data and services. Tempus AI is locking in long‑term, contracted revenue with Bristol Myers Squibb through 2031, pushing into neurology with a $55M Pathos agreement, and embedding itself deeper with Moderna and Merck on cutting‑edge individualized cancer therapies. On the chart, Tempus AI Inc. is acting like a momentum leader, with strong bounces from every pullback and big intraday swings that active traders hunt for.

The flip side is clear. TEM is still losing money at the operating line, running negative free cash flow, and carrying meaningful leverage. The market’s mild selloff after the Moderna–Merck expansion shows that traders are watching profitability and execution, not just headline partnerships. Any stumble in ramping these contracts, or delays in trials like intismeran autogene, can hit sentiment fast.

For disciplined traders, the opportunity is in the volatility and the catalysts. TEM now has a growing stack of multi‑year deals that can drive news flow, guidance updates, and sharp price moves. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.”. In the same spirit, he often reminds his students that “The market rewards prepared traders, not lazy dreamers.” With Tempus AI, that means knowing the key support and resistance levels, understanding how these Bristol Myers Squibb, Pathos, Moderna, and Merck deals affect the story, and being ready to react — not chase. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”